Transurethral resection of the prostate in kidney transplant recipients: urological and renal functional outcomes at long-term follow-up
Correspondence: Alessandro Volpe, Division of Urology, Maggiore Della Carità Hospital, University of Eastern Piedmont, Corso Mazzini, 18, 28100 Novara, Italy.
- To assess prospectively the safety and efficacy of transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms attributable to benign prostatic hyperplasia (BPH) in patients who have undergone renal transplantation (RT).
- To assess the impact of TURP on renal graft function.
Patients and Methods
- Urological and renal functional outcomes of TURP performed in RT recipients for treatment of lower urinary tract obstruction attributable to BPH were prospectively assessed in a series of 32 consecutive patients with follow-up of ≥48 months.
- Maximum urinary flow rate (Qmax) at uroflowmetry, International Prostate Symptom Score (IPSS), post-void residual urine volume (PVR), haemoglobin and serum creatinine (sCr) levels were recorded before TURP and 1, 6, 24 and 48 months after the procedure. The trends in these variables after TURP were evaluated.
- Early and delayed complications were assessed and graded according to the Clavien classification system.
- TURP was performed at a mean of 6 months after RT.
- No intraoperative complications occurred. Seven postoperative complications were observed (21.9%): two Clavien grade II and five Clavien grade IIIa.
- Qmax, IPSS and PVR improved significantly after surgery and the improvement was maintained until 48 months. No patient required a repeat TURP during follow-up.
- SCr levels significantly decreased 1 and 6 months after TURP and did not significantly increase at long-term follow-up.
- TURP for lower urinary tract obstruction attributable to BPH in RT recipients is safe and effective since it improves urinary flow, bladder emptying and related urinary symptoms.
- TURP allows an early significant improvement of graft function that is maintained at a follow-up of 48 months.